Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more) Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Resverlogix Corp RVXCF


Primary Symbol: T.RVX

Healthcare Biotechnology
Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the... see more

TSX:RVX - Post Discussion

Resverlogix Corp > Some news finally!
View:
Post by ENEMENEMYNEMO on May 09, 2022 7:22am

Some news finally!

Resverlogix Announces Type C Meeting with FDA for CORAL, a Phase 3 High-risk COVID-19 Outpatient Study

Comment by ENEMENEMYNEMO on May 09, 2022 7:28am
Unfortunately it's crappy news....they are canning the current study, which we have all been waiting  for UFB... August as a meeting date only ...long term Covid???? This will go on for at least another 2 years to assess any clinical outcomes...more income  $$ in McCrappity's pocket. "Resverlogix will conclude its Phase 2 trial in hospitalized COVID-19 patients early, thus ...more  
Comment by Frogprince on May 09, 2022 10:20am
Good news DM was not mentioned and the Quote was from Ever send.Maybe we are seeing DM move back.
Resverlogix Corp